Celecoxib capsule (I), a wholly owned subsidiary of Shanghai Shanghai Pharmaceutical Innovation Pharmaceutical Development, received the "Drug Clinical trial approval notice" approved and issued by the State Drug Administration, and will start clinical trials of improved new drugs in the near future. Celecoxib is a new generation of non-steroidal anti-inflammatory and analgesic drugs.